文献速递淋巴瘤

BREVITY II期研究:不适合化疗的经典霍奇金淋巴瘤患者一线应用维布妥昔单抗的疗效

Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY).
PubMed 文献 · Br J Haematol · 2020-09-14

英国国家癌症研究所开展II期研究,评估维布妥昔单抗(BV)用于因年龄、衰弱或合并症不适合标准化疗的初治经典霍奇金淋巴瘤(cHL)患者的安全性和疗效。35例可评估毒性,中位年龄77岁,中位CIRS-G评分6分;结论提示BV单药耐受但疗效欠佳,联合其他药物可能更有效。

要点

  • BV单药在老年/合并症cHL初治患者中可耐受但疗效有限。
  • 88%不良事件为1/2级,但27例(77%)发生≥3级不良事件。

核心结论

  • BV单药在不适合标准化疗的初治cHL患者中可耐受但疗效欠佳。
  • 联合其他药物可能提高疗效。

研究设计与样本

  • 英国国家癌症研究所II期研究,采用反应指导设计。
  • 35例可评估毒性,31例可评估疗效;中位年龄77岁,中位CIRS-G评分6分。

主要发现

  • 共报告716例不良事件,626例(88%)为1/2级;27例(77%)患者至少发生1例≥3级不良事件。
  • 14例因毒性减量,11例因不良事件停止治疗。

临床怎么用

  • BV单药可作为不适合标准化疗cHL患者的可选方案,但需权衡疗效与毒性。
  • 考虑联合其他药物以提高疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Standard treatment for classical Hodgkin lymphoma (cHL) is poorly tolerated in older patients and results disappointing. We assessed safety and efficacy of brentuximab vedotin (BV), in previously untreated patients with cHL unfit for standard treatment due to age, frailty or comorbidity. The primary outcome was complete metabolic response (CMR) by positron emission tomography/computed tomography after four BV cycles (PET4). The secondary outcomes included progression-free survival (PFS), overall survival (OS), and toxicity. In all, 35 patients with a median age of 77 years and median total Cumulative Illness Rating Scale for Geriatrics (CIRS-G) score of 6 were evaluable for toxicity and 31 for response. A median of four cycles were given (range one-16). In all, 14 patients required dose reduction due to toxicity and 11 patients stopped treatment due to adverse events (AEs). A total of 716 AEs were reported, of which 626 (88%) were Grade 1/2 and 27 (77%) patients had at least one AE Grade ≥3. At PET4, CMR was 25·8% [95% confidence interval (CI) 13·7-42.2%] and objective response rate 83·9% (95% CI 63·7-90·8%). Median PFS was 7·3 months (95% CI 5·2-9·0), and OS 19·5 months. Our results suggest that BV monotherapy is tolerable but suboptimal in the front-line therapy of elderly or comorbid patients with cHL. Combining BV with other agents may be more effective. Trial Registration: Clinicaltrials.gov identifier: NCT02567851.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Gibb A, Pirrie SJ, Linton K, et al. Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY). Br J Haematol. 2020. PMID: 32926420. doi:10.1111/bjh.17073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。